Topic Review
Genistein’s Effects in Preclinical Models of Cervical Cancer
Cervical cancer is the fourth most commonly diagnosed cancer among women worldwide. While treatments exist to stop growth of cervical cancer in humans, they are often associated with major side effects and the development of resistance to therapy. Traditionally, plant-derived compounds have been used to treat many ailments, including cancer. The search for novel plant-derived chemicals is important, as they can potentially provide effective treatment with less severe side effects and importantly overcome drug resistance. Genistein and its analogues have been shown to decrease survival and proliferation as well as induce cell death in cell culture models of cervical cancer and reduce tumor volume in a mouse model. 
  • 149
  • 27 Dec 2023
Topic Review
Mechanistic Insights into Eosinophilic Esophagitis
Eosinophilic esophagitis (EoE) is a chronic inflammatory disease characterized by eosinophilic infiltration of the esophagus. It arises from a complex interplay of genetic predisposition (susceptibility loci), environmental triggers (allergens and dietary antigens), and a dysregulated immune response, mainly mediated by type 2 T helper cell (Th2)-released cytokines, such as interleukin (IL)-4, IL-5, and IL-13.
  • 127
  • 27 Dec 2023
Topic Review
Management of Chronic Obstructive Pulmonary Diseases
Chronic obstructive pulmonary disease (COPD) is a common, progressive respiratory disease that is growing in prevalence worldwide. The Global Initiative for Chronic Obstructive Lung Disease (GOLD 2023) defines COPD “as a heterogeneous lung condition characterized by chronic respiratory symptoms (dyspnea, cough, expectoration and/or exacerbations) due to abnormalities of the airways (bronchitis, bronchiolitis) and/or alveoli (emphysema) that cause persistent, often progressive, airflow obstruction.”. GOLD is a well-known international organization, which is working to provide guidelines for COPD diagnosis, treatment, prevention, and management in order to assess the characteristics of COPD at a global scale, and to maximize available resources to support COPD care. In COPD management, pharmacological and non-pharmacological treatments are mostly administrated together.
  • 141
  • 27 Dec 2023
Topic Review
Role of NMDA Receptor in Response to Pressure
Professional divers exposed to pressures greater than 11 ATA (1.1 MPa) may suffer from high-pressure neurological syndrome (HPNS). Divers who use closed-circuit breathing apparatus and patients and medical attendants undergoing hyperbaric oxygen therapy (HBOT) face the risk of CNS hyperbaric oxygen toxicity (HBOTx) at oxygen pressure above 2 ATA (0.2 MPa). Both syndromes are characterized by reversible central nervous system (CNS) hyperexcitability, accompanied by cognitive and motor deficits, and N-methyl-D-aspartate receptor (NMDAR) plays a crucial role in provoking them. Various NMDAR subtypes respond differently under hyperbaric conditions. The augmented currents observed only in NMDAR containing GluN2A subunit increase glutamatergic synaptic activity and cause dendritic hyperexcitability and abnormal neuronal activity. Removal of the resting Zn2+ voltage-independent inhibition exerted by GluN2A present in the NMDAR is the major candidate for the mechanism underlying the increase in receptor conductance. 
  • 160
  • 27 Dec 2023
Topic Review
Repurposing Therapeutic Drugs Complexed to Vanadium in Cancer
Repurposing drugs by uncovering new indications for approved drugs accelerates the process of establishing new treatments and reduces the high costs of drug discovery and development. Metal complexes with clinically approved drugs allow further opportunities in cancer therapy. Many vanadium compounds have previously shown antitumor effects, which makes vanadium a suitable metal to complex with therapeutic drugs, potentially improving their efficacy in cancer treatment.
  • 161
  • 27 Dec 2023
Topic Review
Thymoquinone in Colorectal Cancer
Thymoquinone (TQ) is a member of the monoterpene class of compounds, which are formally derived from the condensation of two isoprene units. Thymoquinone has shown the ability to inhibit colorectal cancer (CRC) cells, demonstrating that it can be tentatively considered as a candidate for therapy or adjunctive treatment of CRC.
  • 168
  • 27 Dec 2023
Topic Review
Children with Rare Nager Syndrome
Nager syndrome is a rare human developmental disorder characterized by craniofacial defects including the downward slanting of the palpebral fissures, cleft palate, limb deformities, mandibular hypoplasia, hypoplasia or absence of thumbs, microretrognathia, and ankylosis of the temporomandibular joint. The prevalence is very rare and the literature describes only about a hundred cases of Nager syndrome. 
  • 134
  • 27 Dec 2023
Topic Review
Tyrosine Kinase Inhibitors in BCLC-B Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) represents an entity of poor prognosis, especially in cases of delayed diagnosis. Tyrosine kinase inhibitors (TKIs) have multiple anti-tumor effects and are widely used in several types of cancers. They down-regulate different molecular pathways that take part in carcinogenesis. The primary targets are the tyrosine kinase receptors (RTKs), key proteins that regulate cancer growth and metastasis. Specifically, TKIs block the phosphorylation of tyrosine kinases and the subsequent signaling pathways, slowing down cancer growth. Some of the inhibited networks are the rat sarcoma (RAS)/mitogen-activated protein kinases (MAPKs), phosphoinositide 3-kinase (Pi3K)/protein kinase B (AKT)/mechanistic target of rapamycin (mTOR), phospholipase C (PLC)/Ca2+/calmodulin-dependent protein kinase-protein kinase C (CaMK-PKC), Janus kinase (JAK)/signal transducer and activator of transcription protein family (STAT), epidermal growth factor receptor (EGFR), vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR), platelet-derived growth factor receptor (PDGFR), hepatocyte growth factor receptor (HGFR, Met), and RAF kinases. Due to their multiple actions, TKIs were the standard treatment of care in advanced HCC over the last 15 years, but after the induction of IO, they now comprise the second-line option.
  • 105
  • 27 Dec 2023
Topic Review
Antithrombotic Therapy in Patients with AF Undergoing PCI
The antithrombotic management of patients with atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI) poses numerous challenges. Triple antithrombotic therapy (TAT), which combines dual antiplatelet therapy (DAPT) with oral anticoagulation (OAC), provides anti-ischemic protection but increases the risk of bleeding. Therefore, TAT is generally limited to a short phase (1 week) after PCI, followed by aspirin withdrawal and continuation of 6–12 months of dual antithrombotic therapy (DAT), comprising OAC plus clopidogrel, followed by OAC alone.
  • 170
  • 27 Dec 2023
Topic Review
CD147/Basigin in Malignant Tumors and T-Cell-Mediated Immunological Disorders
CD147/Basigin, a transmembrane glycoprotein belonging to the immunoglobulin superfamily, is a multifunctional molecule with various binding partners. CD147 binds to monocarboxylate transporters (MCTs) and supports their expression on plasma membranes. MTC-1 and MCT-4 export the lactic acid that is converted from pyruvate in glycolysis to maintain the intracellular pH level and a stable metabolic state. Under physiological conditions, cellular energy production is induced by mitochondrial oxidative phosphorylation. Glycolysis usually occurs under anaerobic conditions, whereas cancer cells depend on glycolysis under aerobic conditions. T cells also require glycolysis for differentiation, proliferation, and activation. Human malignant melanoma cells expressed higher levels of MCT-1 and MCT-4, co-localized with CD147 on the plasma membrane, and showed an increased glycolysis rate compared to normal human melanocytes. CD147 silencing by siRNA abrogated MCT-1 and MCT-4 membrane expression and disrupted glycolysis, inhibiting cancer cell activity. Furthermore, CD147 is involved in psoriasis. MCT-1 was absent on CD4+ T cells in CD147-deficient mice. The naïve CD4+ T cells from CD147-deficient mice exhibited a low capacity to differentiate into Th17 cells. Imiquimod-induced skin inflammation was significantly milder in the CD147-deficient mice than in the wild-type mice. Overall, CD147/Basigin is involved in the development of malignant tumors and T-cell-mediated immunological disorders via glycolysis regulation.
  • 273
  • 26 Dec 2023
  • Page
  • of
  • 1352
Video Production Service